Dr. Gilles Divita is a cofounder and CEO of DivinCell SAS (FR) and Chief Scientist at Aanastra, Inc, California (USA), companies that are pioneering novel peptide-based RNA therapeutic drug delivery for the treatment of cancer and genetic diseases. 

Dr. Divita has over 25 years of experience in drug delivery systems, peptide-drugs and oligonucleotide therapeutics. Dr Divita’s work focuses on strategies to probe and perturb the behavior of biomolecules in physiological and pathological settings. He is the pioneer of the “non covalent cell penetrating peptide-based strategy” for therapeutic delivery and inventor of the peptide-based platform that is used by Aadigen and Divincell for its RNA therapeutic strategy. Dr. Divita is author of over 200 articles in peer reviewed scientific journals and of 25 patents. 

Dr. Divita holds a Ph.D. in Biochemistry/Biophysics from the University in Lyon, France. 

He worked as a Scientist at the Max Planck Institute for Medical Research in Heidelberg-Germany and then as Associate Professor at the SCRIPPS Research Institute, La Jolla, USA.  In 1996, Dr. Divita joined the French National Center for Scientific Research (CNRS) and was Research Director, Head of Chemical Biology and Nanotechnology for the Therapeutics Team at the CNRS in Montpellier-France from 1999 to 2016. In 2018 he cofounded Divincell with Neil Desai.